Form 10-K InMed Pharmaceuticals For: Jun 30

Related Keywords

United States ,Netherlands ,Italy ,New Zealand ,United Kingdom ,Spain ,Canada ,Quebec ,Washington ,Australia ,China ,Montreal ,Germany ,India ,Austria ,New York ,Israel ,Vancouver ,British Columbia ,California ,Province Of British Columbia ,South San Francisco ,Japan ,Serbia ,Greece ,Brazil ,Russia ,France ,Italian ,Americans ,American ,Australian ,British ,America ,Canadian ,Great Britain ,Chinese ,Nicole Lemerond ,Erica Adams ,Vikramaditya Yadav ,Amryt Pharma Filsuvez ,Bryan Baldasare ,Mauro Maccarrone ,Ujendra Kumar ,Aducanumab Aduhelm ,Lecanemab Leqembi ,Brimonidine Alphagan ,Andrew Hull ,Jonathan Tegge ,Eli Lilly ,National Research Council Of Canada ,Master Service Agreement ,Inmed Pharmaceuticals Inc ,Products Grants Program ,National Research Council Canada ,Clinical Health ,European Commission ,Exchange Commission ,Development Pipeline Of Therapeutic Drug Candidates ,A Company ,Payments Program ,Public Accounting Firm ,Us Public Company Accounting Oversight Board ,Name Of Each Exchange On Which ,Single Convention On Narcotic Drugs ,European Union ,Audit Committee ,Office Of Orphan Products Development ,Development Intangible ,Nasdaq ,Border Protection Service ,National Epidermolysis Bullosa Registry ,Our Collaborative Research Agreement ,Clinical Development ,Centers For Medicare ,Human Services ,Chemical Synthesis For The Development ,Skye Biosciences Inc ,Collaborative Research Agreement ,Inmed Pharmaceutical Ltd ,Health Wellness ,Cannabinoid Analogs In Pharmaceutical Drug Development ,Drug Administration ,Industrial Research Assistance Program ,National Eb Registry ,Device Safety Authority ,Medicaid Services ,Deposit Insurance Corporation ,National Coverage Determination ,United States Department Of Health ,Drug Enforcement Administration ,Trademark Office ,Centers For Medicare Medicaid Services ,Us Health Insurance Portability ,Development Of Inmed ,Regulatory Affairs ,Office Of Inspector ,Company Baymedica ,Public Company Accounting Oversight Board United States ,Inmed Pharmaceuticals The ,Research Development ,Web Program ,Almac Group United Kingdom ,Department Of Justice ,Securities Exchange ,Genentech ,Party Transactions ,Data Monitoring Committee ,Biogen Science Inc ,European Medicines Agency ,Nasdaq Hearings Panel The ,Office Of The United States Trade Representative ,Clinical Sciences ,Therapeutic Goods Administration ,University Of British Columbia ,Biosynthesis Technologies For The Development ,Faculty Of Pharmaceuticals Sciences ,Sweetnam Consulting Inc ,Discovery Research ,Health Information Technology For Economic ,Inmed Pharmaceuticals Inc On ,Zealand Customs Service ,Animals In Group ,Company Proxy Statement ,Baymedica Inc ,Neurodegenerative Diseases Program ,Canadian Deposit Insurance Corporation ,Biogen Sciences Inc ,Department Of Biotechnological ,Health Technology Assessment ,National Competent Authorities ,Neither Of The Company ,Brio Financial Group ,Regulatory Incentives For Orphan Product Development ,Material Services Agreement ,Technology Assignment Agreement ,Partner Of Norton Rose Fulbright Canada ,European Cannabinoid Research Alliance ,National Competent Authorities Ncas ,Canada Border Services Agency ,Audit Committee Of The Board Directors ,Preclinical Research ,Health Canada ,Ocular Formulation Development ,Mark One ,Zip Code ,Exchange Act ,Each Exchange On Which ,Securities Exchange Act ,Interactive Data File ,Regulations T ,Sarbanes Oxley Act ,Annual Report ,Financial Condition ,Private Securities Litigation Reform Act ,Product Candidates ,New Chemical Entities ,Business Corporations Act ,Med Pharmaceuticals Inc ,General Manager ,Vice Presidents ,Synthetic Biology ,Employee Handbook ,Business Conduct ,Cannabinoid Analogs ,Pharmaceutical Drug Development ,Kindler Syndrome ,Contemplated Clinical Development ,Cannabinoid Products ,Wellness Sector ,Product Candidate ,Flexible Suite ,Chemical Engineering ,Development Project ,Metabolic Engineering ,Chemical Synthesis ,Biosynthesis Technologies ,Their Variants ,Synthesis Derived Cannabinoids Commercialized ,North American ,New Chemical ,New Chemical Entity ,Ginko Bioworks ,National Research Council ,Almac Group ,Milestones Include ,Good Manufacturing Practice ,Development Pipeline ,Therapeutic Drug ,Krystal Biotech ,Chiesi Farmaceutici Spa ,Creek Biosciences ,Recessive Dystrophic Epidermolysis ,Orphan Products Development ,Orphan Drug Designation ,Orphan Products Grants Program ,Orphan Product ,Ethics Committees ,Fast Track ,Breakthrough Therapy ,Accelerated Review ,Epidermolysis Bullosa ,Clinical Trial Applications ,African Americans ,Mexican Americans ,Glaucoma Treatment ,Intraocular Pressure Lowering Drugs ,Rho Kinase ,Skye Biosciences ,Emerald Biosciences ,Preclinical Results ,Drug Candidate ,Cell Death ,Vehicle Control ,Pharmacokinetic Solver ,Non Compartmental Analysis ,New Zealand White ,Modulates Neuroprotection ,Intraocular Pressure ,Potential Multi Target Therapeutic Intervention ,Biophysical Acta ,Investigational New Drug ,Chemistry Manufacturing ,Age Related Macular Degeneration ,Endocannabinoid System ,Treat Neurodegenerative ,Patent Cooperation Treaty ,Treating Neuronal Disorders ,Applied Clinical Sciences ,European Cannabinoid Research ,Pharmaceuticals Sciences ,Canadian Neuroscience Meeting ,Active Pharmaceutical Ingredients ,Med Patent Portfolio ,Medica Patent Portfolio ,Chemical Entity ,Patent Cooperation ,Corrupt Practices Act ,Canadian Corruption ,Foreign Public Officials Act ,Annual Form ,Institutional Review Boards ,Risk Evaluation ,Mitigation Strategy ,United States Department ,Inspector General ,United States Attorney ,Controlled Substances Act ,Border Protection ,Australian Customs ,New Zealand Medicines ,Medical Device Safety Authority ,New Zealand Customs Service ,Medicare Modernization Act ,Anti Kickback Statute ,Insurance Portability ,Accountability Act ,Health Information Technology ,Clinical Health Act ,Physician Payment Sunshine Act ,Open Payments Program ,European Economic Area ,Single Convention ,Narcotic Drugs ,General Data Protection Regulation ,Australian Privacy Act ,Company Accounting Oversight Board ,Restated Stock Option Plan ,Annual General Meeting ,Competition Act ,Canadian Competition Tribunal ,Investment Canada Act ,Financial Position ,Baymedica Products ,Marketing Authorization Applications ,Canadian Income Tax Act ,Financial Accounting Standards Board ,United States Trade Representative ,Drug Price Competition ,Patent Term Restoration Act ,Nasdaq Capital Market ,Securities Act ,Note Regarding Forward Looking Statements ,Inmed Pharmaceuticals ,Biogen Science ,Accounting Standards Update ,Going Concern ,Accounting Policies ,Significant Judgments ,Intangible Assets ,In Process Research ,Financial Statements ,Year Ended June ,Independent Registered Public Accounting ,Public Company Accounting Oversight Board ,Consolidated Financial ,Paid During ,Med Pharmaceuticals ,Hastings Street ,United States Securities ,Sweetnam Consulting ,Federal Deposit Insurance Corporation ,Long Lived Assets ,Per Share ,Share Based Payments ,Common Stock ,Development Costs ,Intellectual Property Costs ,Use Assets ,Purchase Price ,Placement Offering ,Additional Paid In ,Private Placement Offerings ,Baymedica Agreement ,Agent Investment Options ,Options Issued During ,Average Fair Value ,Grant Date ,Options Granted ,Simplified Method ,Share Based Payment Transactions ,Chief Operating Decision Maker ,Chief Executive Officer ,Ended June ,Assignment Agreement ,Research Agreement ,License Agreement ,Arbitration Act ,Janet Grove ,Norton Rose Fulbright Canada ,From February ,Nasdaq Listing Rule ,Nasdaq Hearings Panel ,Disclosure Controls ,Internal Control ,Sponsoring Organizations ,Treadway Commission ,Internal Control Integrated Framework ,Chief Financial Officer ,Previously Reported Material ,Financial Reporting ,Corporate Governance ,Beneficial Ownership Reporting Compliance ,Proxy Statement ,Certain Beneficial Owners ,Compensation Plan ,Related Person ,Exhibit Index ,Principal Accounting ,Principal Executive Officer ,Principal Financial ,